Isomorphic Labs, affiliated with Alphabet, collaborates with Lilly and Novartis on AI-driven drug discovery initiatives.
In Brief
Isomorphic Labs has successfully concluded two major agreements with renowned pharmaceutical companies, Eli Lilly and Novartis, aimed at advancing drug discovery through artificial intelligence.
Isomorphic — a London-based drug discovery company operating under Alphabet The partnerships amount to nearly $3 billion in total financial commitments. Eli Lilly and Novartis According to the agreement, Isomorphic Labs will collaborate with Lilly on developing small molecule therapeutics across a variety of targets, starting with a cash upfront of $45 million.
"We’re delighted to start this partnership and utilize our cutting-edge technology platform and substantial computational resources to support Lilly’s developmental initiatives,\" stated Demis Hassabis, CEO and founder of Isomorphic Labs.
"The shared commitment to advancing revolutionary drug design techniques and our mutual appreciation for leading-edge science makes this collaboration particularly exciting,\" he added.
In a similar vein, Isomorphic has secured an agreement with Novartis, which also resembles the partnership with Lilly, involving an initial cash payment of $37.5 million and the potential to earn up to $1.2 billion in milestone payments. Isomorphic will focus on identifying small molecules that target three undisclosed disease-related objectives.
Utilizing AlphaFold AI for Drug Discovery Optimization.
DeepMind’s AlphaFold AI technology, the core of Isomorphic’s approach, is recognized for its capabilities in predicting protein structures, which is set to expedite the processes of target discovery and compound formulation.
Both collaborations will rest on Google Operating as an independent entity within Alphabet, Isomorphic Labs is fully dedicated to harnessing AI for advancements in drug discovery. The company is aiming to fundamentally alter how drugs are discovered, applying a distinctly AI-focused methodology.
Isomorphic Labs is striving to develop predictive and generative models that can foresee drug efficacy and create innovative molecular compounds.
By leveraging its insights, Isomorphic Labs cultivates a thorough comprehension of the biological mechanisms at play for drug targets, which enables the informed design of new therapeutic solutions.
By integrating AlphaFold with other AI models Isomorphic Labs' collaboration with both Lilly and Novartis illustrates the evolving landscape of pharmaceutical science.
Disclaimer
In line with the Trust Project guidelines Kumar, an accomplished Tech Journalist, focuses on the vibrant intersections of AI/ML, marketing tech, and emerging trends in fields like cryptocurrency, blockchain, and NFTs. With over three years of solid experience in the industry, Kumar has demonstrated exceptional aptitude in crafting vibrant narratives, conducting meaningful interviews, and delivering insightful analyses. His expertise includes producing high-impact materials, such as articles, reports, and research for reputable platforms. Combining technical acumen with compelling storytelling, Kumar effectively translates complex technological concepts to a broad audience in an engaging and clear manner.
